Unlock instant, AI-driven research and patent intelligence for your innovation.

Human vascular smooth muscle cell l-type calcium channel immunogenic peptide and its vaccine and application

A vascular smooth muscle, immunogenic technology, applied in the field of biotechnology and medicine, can solve problems such as blocking channels, and achieve the effect of good blood pressure, good effect, and blood pressure lowering.

Active Publication Date: 2022-05-13
WUHAN HUAJIYUAN BIOTECH DEV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, no active or passive immunization method has been used to block this channel in the world.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human vascular smooth muscle cell l-type calcium channel immunogenic peptide and its vaccine and application
  • Human vascular smooth muscle cell l-type calcium channel immunogenic peptide and its vaccine and application
  • Human vascular smooth muscle cell l-type calcium channel immunogenic peptide and its vaccine and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Preparation of Immunogenic Peptides of Human Vascular Smooth Muscle Cell L-Type Calcium Channels

[0034]Based on bioinformatics techniques such as amino acid hydrophilicity, antigenicity, and sequence space conformation to predict B cell epitopes, 4 immunogenic peptides targeting L-type calcium channels were designed: VPAEDDPSPC, DSSKQTEAECK, DSHTEDKGPI, and CAPESEPSNSTE. A PSSM-8 automatic peptide synthesizer (SHIMADZU, Japan) was used to synthesize peptides, and the purity of the synthesized peptides was analyzed by high performance liquid chromatography to reach more than 95%. The obtained peptides were lyophilized, aliquoted, placed in cryopreservation tubes, and stored at -80°C for later use.

Embodiment 2

[0035] Example 2 Preparation of Vascular Smooth Muscle Cell L-Type Calcium Channel Immunogenic Peptide-Carrier Vaccine

[0036] Using the Qβ-2aa bacteriophage virus-like particle protein, four kinds of peptide-vector vaccines Qβ-VC10, Qβ-DK11, Qβ-DI10, and Qβ-CE12 were prepared. The specific preparation process is as follows:

[0037] 1. Preparation of Qβ-2aa phage virus-like particle protein: the English abbreviation of Qβ-2aa phage virus-like particle protein is: Qβ-2aa VLP, and Qβ-2aa VLP is used to represent Qβ-2aa bacteriophage virus-like particle protein hereinafter. It is prepared as follows:

[0038] 1) Obtaining a recombinant strain expressing Qβ-2aa VLP: the recombinant strain is Escherichia coli DH5α / pGEXQβ-A1, which can induce the production of Qβ-2aa VLP protein. The preservation number of Escherichia coli DH5α / pGEXQβ-A1 is CCTCCNO: M209282. For the specific preparation process, please refer to the Chinese patent: A preparation method and application of Qβ-2aa ph...

Embodiment 3

[0048] Example 3 Study on the antihypertensive effect of human vascular smooth muscle cell L-type calcium channel immunogenic peptide-carrier vaccine

[0049] Male spontaneously hypertensive rats (SHR) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and the animals were raised in the SPF animal experiment center of Tongji Medical College, using 12h / 12h light and non-restricted normal diet. Specifically divided into 7 groups: PBS control group, VLP group, Qβ-VC10 vaccine group, Qβ-DK11 vaccine group, Qβ-DI10 vaccine group, Qβ-CE12 vaccine group, amlodipine gavage group, the number of each group is 8 Only. Immunization and gavage started from the age of 6 weeks, the dose of gavage group was 5mg / kg / d, PBS control group, VLP group, Qβ-VC10 vaccine group, Qβ-DK11 vaccine group, Qβ-DI10 vaccine group, Qβ-CE12 vaccine group In the group, the same volume of vaccine, Qβ-2aa and PBS was taken, the dose was 300ug / rat, and the rats were subcutaneously ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a human vascular smooth muscle cell L-type calcium channel immunogenic peptide and its vaccine and application. The human vascular smooth muscle cell L-type calcium channel immunogenic peptide is any one of the following four peptides , and their amino acid sequences are VPAEDDPSPC, DSSKQTEAECK, DSHTEDKGPI and CAPESEPSNSTE, respectively. The vascular smooth muscle cell L-type calcium channel immunogenic peptide is coupled with the recombinant Qβ-2aa bacteriophage virus-like particle protein, and is repeatedly and orderedly arranged on the surface of the virus-like particle to form a polypeptide-carrier vaccine. The application of the vaccine in the treatment of essential hypertension is disclosed. The vaccine can induce high-titer specific antibodies in experimental animals, and can significantly reduce the blood pressure of spontaneously hypertensive rats.

Description

technical field [0001] The invention relates to the fields of biotechnology and medicine, in particular to a human vascular smooth muscle cell L-type calcium channel immunogenic peptide, vaccine and application thereof. Background technique [0002] Hypertension is a worldwide problem that seriously endangers human health. According to the statistical results of "China Cardiovascular Disease Report 2017", there are currently about 270 million people in my country with high blood pressure, 13 million strokes, 11 million coronary heart disease, 4.5 million heart failure, and heart disease. Vascular mortality ranks first among all diseases. Although many chemical drugs are used in the treatment of hypertension, the poor compliance, low treatment rate (40%) and low control rate (10%) of hypertension in China are still unsolved problems, so the high incidence of hypertensive complications , seriously endangering human health. Therapeutic antihypertensive vaccine has the advantag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/705A61K39/00A61K39/385A61P9/12
CPCA61K39/0005A61K39/385A61P9/12C07K14/705A61K2039/6081A61K2039/6075
Inventor 廖玉华陈霄王一逸邱志华廖梦阳
Owner WUHAN HUAJIYUAN BIOTECH DEV